Generate Biomedicines, Inc. (GENB)
Generate Biomedicines will go public soon. The estimated IPO date is February 27, 2026.
IPO Price Range
$15.00 - $17.00
Shares Offered
25,000,000
Deal Size
$400.00M

Generate Biomedicines Statistics

Total Valuation

GENB has a market cap or net worth of $2.04 billion. The enterprise value is $1.89 billion.

Market Cap 2.04B
Enterprise Value 1.89B

Important Dates

Earnings Date n/a
Ex-Dividend Date n/a

Share Statistics

GENB has 127.45 million shares outstanding.

Current Share Class n/a
Shares Outstanding 127.45M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float n/a

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 63.94
Forward PS n/a
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 59.13
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

Current Ratio n/a
Quick Ratio n/a
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage 18.79

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -67.53%
Return on Invested Capital (ROIC) n/a
Return on Capital Employed (ROCE) n/a
Weighted Average Cost of Capital (WACC) n/a
Revenue Per Employee $102,221
Profits Per Employee -$651,135
Employee Count 312
Asset Turnover n/a
Inventory Turnover n/a

Taxes

In the past 12 months, GENB has paid $163,000 in taxes.

Income Tax 163,000
Effective Tax Rate n/a

Stock Price Statistics

Beta (5Y) n/a
52-Week Price Change n/a
50-Day Moving Average n/a
200-Day Moving Average n/a
Relative Strength Index (RSI) n/a
Average Volume (20 Days) n/a

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, GENB had revenue of $31.89 million and -$203.15 million in losses. Loss per share was -$1.59.

Revenue31.89M
Gross Profit 31.89M
Operating Income -235.07M
Pretax Income -202.99M
Net Income -203.15M
EBITDA -224.93M
EBIT -235.33M
Loss Per Share -$1.59
Full Income Statement

Balance Sheet

The company has $221.84 million in cash and $68.53 million in debt, with a net cash position of $153.31 million or $1.20 per share.

Cash & Cash Equivalents 221.84M
Total Debt 68.53M
Net Cash 153.31M
Net Cash Per Share $1.20
Equity (Book Value) -615.97M
Book Value Per Share -4.83
Working Capital 152.16M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$200.62 million and capital expenditures -$3.51 million, giving a free cash flow of -$204.13 million.

Operating Cash Flow -200.62M
Capital Expenditures -3.51M
Free Cash Flow -204.13M
FCF Per Share -$1.60
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -737.04% and -636.99%.

Gross Margin 100.00%
Operating Margin -737.04%
Pretax Margin -636.48%
Profit Margin -636.99%
EBITDA Margin -705.27%
EBIT Margin -737.86%
FCF Margin -640.06%

Dividends & Yields

GENB does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield n/a
Earnings Yield -9.96%
FCF Yield -10.01%

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

GENB has an Altman Z-Score of 4.07.

Altman Z-Score 4.07
Piotroski F-Score n/a